Reply to thread

Message

<blockquote data-quote="tD33NAt" data-source="post: 2415251" data-attributes="member: 124445">Eisai Co., Ltd. (Headquarters: Tokyo, President &amp; CEO: Haruo Naito) announced that it has submitted a Marketing Authorization Application (MAA) to the Japanese Ministry of Health, Labour and Welfare seeking approval for SEP-190 (generic name: eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia.&nbsp;&nbsp; SEP-190 is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic) that is effective in treating transient and chronic insomnia and that can be used over the long-term without patients developing a tolerance resistance to it...<a href="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a><a href="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/zubT3GdX9qo" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/zubT3GdX9qo/3NnH" target="_blank">More...</a></blockquote>

[QUOTE="tD33NAt, post: 2415251, member: 124445"] Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that it has submitted a Marketing Authorization Application (MAA) to the Japanese Ministry of Health, Labour and Welfare seeking approval for SEP-190 (generic name: eszopiclone), a product the company has been developing in Japan, as a treatment for insomnia. SEP-190 is a non-benzodiazepine type GABAA agonist (non-benzodiazepine sedative hypnotic) that is effective in treating transient and chronic insomnia and that can be used over the long-term without patients developing a tolerance resistance to it...[URL="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/0/da"][IMG]http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/1/da"][IMG]http://feedads.g.doubleclick.net/~a/hCoAiOfNuHkBxyjggI_apFA_aYk/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/zubT3GdX9qo[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/zubT3GdX9qo/3NnH]More...[/url] [/QUOTE]

Name

Verification

Loading…